四川双马（000935）：投资收益表现亮眼，前三季度业绩同比双位数增长

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [5]. Core Views - The company reported a revenue of 917 million RMB and a net profit of 294 million RMB for the first three quarters of 2025, representing year-on-year increases of 23.21% and 20.03% respectively. The non-recurring net profit reached 326 million RMB, up 46.89% year-on-year [2]. - The company is benefiting from a recovery in IPO activities, accelerated delivery of GLP-1 raw material orders, and improved market sentiment, which are expected to drive steady growth in performance [5]. - The investment income for Q3 was 64 million RMB, a year-on-year increase of 77.78%, and the cumulative investment income reached 116 million RMB, a significant improvement from the previous year's loss [3]. Summary by Sections Performance Review - For Q3 2025, the company achieved revenues of 288 million RMB and a net profit of 165 million RMB, with year-on-year increases of 9.91% and 25.74% respectively [2]. - The return on equity (ROE) for the first three quarters was 3.85%, an increase of 0.54 percentage points year-on-year [2]. Operational Analysis - The revenue growth in Q3 was attributed to the management fee income from the pharmaceutical, building materials, and private equity sectors, although there was a decline compared to the previous quarter due to reduced management fees from private equity exits [3]. - The company has successfully advanced several key projects, with multiple investments achieving public listings and others entering the exit phase [3]. Financial Forecast and Valuation - The company is projected to achieve a net profit of 650 million RMB for the full year of 2025, representing a 112% year-on-year growth, with a price-to-earnings (P/E) ratio of 23 times [5]. - The report anticipates that the performance of the equity investment segment will continue to release earnings elasticity as market sentiment improves [3].